Parmax Pharma Intrinsic Value
Parmax Pharma (PARMAX) median intrinsic value is ₹62.04 from 2 valuation models (range ₹19–₹62), vs current price ₹31.02 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. For current market price and key ratios, visit Parmax Pharma share price today.
PARMAX Valuation Methods Summary — DCF, Graham Number & P/E
Parmax Pharma intrinsic value across 2 models vs current price ₹31.02 — upside/downside and value range per method. Browse PARMAX balance sheet details for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Revenue Multiple Method | revenue | ₹62.04 | ₹55.84 - ₹68.24 | +100.0% | Revenue/Share: ₹32.00, P/S: 2.0x |
| Simple DCF (5Y) | dcf | ₹18.57 | ₹14.86 - ₹22.28 | -40.1% | CF Growth: 5.0%, Discount: 15% |
PARMAX Intrinsic Value vs Market Price — All Valuation Models
Parmax Pharma fair value range ₹19–₹62 vs current market price ₹31.02 across 2 valuation models. Compare with PARMAX fundamental valuation to assess whether the stock is under or overvalued.
PARMAX Intrinsic Value Analysis — Undervalued or Overvalued?
Parmax Pharma median intrinsic value ₹62.04, current price ₹31.02 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.
What is the intrinsic value of PARMAX?
Based on our comprehensive analysis using 2 different valuation methods, the estimated intrinsic value of Parmax Pharma (PARMAX) is ₹62.04 (median value). With the current market price of ₹31.02, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹18.57 to ₹62.04, indicating ₹18.57 - ₹62.04.
Is PARMAX undervalued or overvalued?
Based on our multi-method analysis, Parmax Pharma (PARMAX) appears to be trading below calculated value by approximately 100.0%.
PARMAX Financial Health — Key Ratios vs Industry Benchmarks
Parmax Pharma financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 1.25 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | -9.50 | Industry Standard: <0.5 | Below 0.5 | Indicates financial leverage level |
| Return on Equity | 250.0% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | -27.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.84x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
PARMAX Cash Flow Quality — Operating & Free Cash Flow
Parmax Pharma operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-1 Cr | ₹-2 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹0 Cr | ₹-1 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹0 Cr | ₹-1 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹1 Cr | ₹0 Cr | Positive Operating Cash Flow | 6/10 |
| March 2021 | ₹4 Cr | ₹3 Cr | Positive Free Cash Flow | 8/10 |